Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study-Reference-Cited by-同舟云学术

Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study

Published:2023-02 Issue:2 Volume:21 Page:370-379
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Fujii Hideki,Iwaki Michihiro,Hayashi Hideki,Toyoda Hidenori,Oeda Satoshi,Hyogo Hideyuki,Kawanaka Miwa,Morishita Asahiro,Munekage Kensuke,Kawata Kazuhito,Yamamura Sakura,Sawada Koji,Maeshiro Tatsuji,Tobita Hiroshi,Yoshida Yuichi,Naito Masafumi,Araki Asuka,Arakaki Shingo,Kawaguchi Takumi,Noritake Hidenao,Ono Masafumi,Masaki Tsutomu,Yasuda Satoshi,Tomita Eiichi,Yoneda Masato,Kawada Norifumi,Tokushige Akihiro,Kamada Yoshihiro,Takahashi Hirokazu,Ueda Shinichiro,Aishima Shinichi,Sumida Yoshio,Nakajima Atsushi,Okanoue Takeshi

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference44 articles.

1. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

2. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

3. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

4. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease Guidelines 2017-Part 1: definition, risk factors and assessment;Wong;J Gastroenterol Hepatol,2018

5. Long-term follow-up of patients with nonalcoholic fatty liver;Rafiq;Clin Gastroenterol Hepatol,2009

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study;Diabetes, Obesity and Metabolism;2024-09-02

2. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis;The American Journal of Medicine;2024-07

3. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis;Alimentary Pharmacology & Therapeutics;2024-06-03

4. Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD;Frontiers in Endocrinology;2024-05-17

5. Low ankle–brachial index is associated with higher cardiovascular mortality in individuals with nonalcoholic fatty liver disease;European Journal of Medical Research;2024-05-09